Automated Galectin-3 Blood Test Launch - Report on BG Medicine

Jul 21, 2015, 09:25 ET from

NEW YORK, July 21, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on BG Medicine, Inc., (NASDAQ: BGMD). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL:

Highlights from our BGMD Report include:

  • Market availability of ARCHITECT® Galectin-3 assay - In a press release issued on July 6, 2015, BG Medicine, Inc., informed that ARCHITECT® Galectin-3 assay is now available in the market. The Company reported that the ARCHITECT Galectin-3 assay is performed using the Abbott ARCHITECT automated immunoassay analyzer and is being commercialized through an agreement between BG Medicine and the global healthcare  services provider, Abbott. The United States Food and Drug Administration (USFDA) already gave a green signal to the automated blood test.
  • Intended Use of the Test - Elaborating on ARCHITECT Galectin-3 assay's intended use, BG Medicine informed that this test is used with the ARCHITECT i System with STAT protocol capability. As per the release, ARCHITECT Galectin-3 assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of galectin-3 in human serum and EDTA plasma. Providing safety instructions about the test, the Company said that the results from the test should be interpreted along with clinical findings and other laboratory test results. There is a possibility that in patients with certain type of cancers, increase levels of galectin-3 may be found in blood. Likewise, in patients with conditions associated with organ fibrosis, it is possible that levels of galectin-3 in blood may be increased.
  • How Galectin-3 Aids Physicians- With the help of galectin-3 testing, it is possible to identify patient who are at high risk of heart failure. The test is of great help for the physicians to determine which patients are at higher risk of hospitalization or death. In conjunction with clinical evaluation, the test is to be used as an aid in assessing the prognosis of patients with chronic heart failure.
  • Management's Comments - Commenting on the development, the M.D., President and CEO of BG Medicine, Paul R. Sohmer said, "We believe that the introduction of automated galectin-3 testing will improve access to galectin-3 testing, shorten turn-around time for delivery of test results, and, as a result, accelerate adoption of galectin-3 testing in the United States."

To find out how this influences our rating on BG Medicine, Inc., read the full report in its entirety here:

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.